264 related articles for article (PubMed ID: 19920114)
1. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
[TBL] [Abstract][Full Text] [Related]
2. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Yu EY; Massard C; Gross ME; Carducci MA; Culine S; Hudes G; Posadas EM; Sternberg CN; Wilding G; Trudel GC; Paliwal P; Fizazi K
Urology; 2011 May; 77(5):1166-71. PubMed ID: 21539969
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Twardowski PW; Beumer JH; Chen CS; Kraft AS; Chatta GS; Mitsuhashi M; Ye W; Christner SM; Lilly MB
Anticancer Drugs; 2013 Aug; 24(7):743-53. PubMed ID: 23652277
[TBL] [Abstract][Full Text] [Related]
4. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Araujo JC; Mathew P; Armstrong AJ; Braud EL; Posadas E; Lonberg M; Gallick GE; Trudel GC; Paliwal P; Agrawal S; Logothetis CJ
Cancer; 2012 Jan; 118(1):63-71. PubMed ID: 21976132
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
Herold CI; Chadaram V; Peterson BL; Marcom PK; Hopkins J; Kimmick GG; Favaro J; Hamilton E; Welch RA; Bacus S; Blackwell KL
Clin Cancer Res; 2011 Sep; 17(18):6061-70. PubMed ID: 21810917
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD; Kollmannsberger CK; Sukhai MA; Takebe N; Kamel-Reid S; Siu LL; Hotte SJ
Invest New Drugs; 2014 Oct; 32(5):1005-16. PubMed ID: 24788563
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
Miller AA; Pang H; Hodgson L; Ramnath N; Otterson GA; Kelley MJ; Kratzke RA; Vokes EE;
J Thorac Oncol; 2010 Mar; 5(3):380-4. PubMed ID: 20087228
[TBL] [Abstract][Full Text] [Related]
11. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Antonarakis ES; Heath EI; Posadas EM; Yu EY; Harrison MR; Bruce JY; Cho SY; Wilding GE; Fetterly GJ; Hangauer DG; Kwan MF; Dyster LM; Carducci MA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):883-92. PubMed ID: 23314737
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.
Ryan CJ; Shah S; Efstathiou E; Smith MR; Taplin ME; Bubley GJ; Logothetis CJ; Kheoh T; Kilian C; Haqq CM; Molina A; Small EJ
Clin Cancer Res; 2011 Jul; 17(14):4854-61. PubMed ID: 21632851
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Brooks HD; Glisson BS; Bekele BN; Johnson FM; Ginsberg LE; El-Naggar A; Culotta KS; Takebe N; Wright J; Tran HT; Papadimitrakopoulou VA
Cancer; 2011 May; 117(10):2112-9. PubMed ID: 21523723
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 trial of dasatinib in advanced melanoma.
Kluger HM; Dudek AZ; McCann C; Ritacco J; Southard N; Jilaveanu LB; Molinaro A; Sznol M
Cancer; 2011 May; 117(10):2202-8. PubMed ID: 21523734
[TBL] [Abstract][Full Text] [Related]
16. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
18. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).
Dorff TB; Quinn DI; Pinski JK; Goldkorn A; Sadeghi S; Tsao-Wei D; Groshen S; Kuhn P; Gross ME
Clin Genitourin Cancer; 2019 Aug; 17(4):241-247.e1. PubMed ID: 31227432
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
